Avid Bioservices Inc (CDMO)

[RRdog]

Geo,

Again, the company strong enough, in the Hepc arena, that still needs another ingredient for their cocktail, wants to compete-- particularly internationally, and has plenty of money is Roche.

IMO PPHM has plenty of data to supply Roche re the delayed action re Bavi vs INF to interest them. The possibility of replacing INF is a big carrot.

Even a modest upfront payment of 20-50mm plus milestones would be very helpful to PPHM re cash burn and dilution over the next 6 months. This dollar amount and the short term testing (remember viral is much faster than cancer) would not be much burden to Roche. Also, remember that Roche recently acquired Anadysis for approx 300mm as an ante into this game. That acquisition was in full knowlege of all VRUS activity in this field as Roche was a Pharmasset partner. In light of todays news, this gets more interesting.

All IMO
RRdog